Lessons from phase III clinical trials on anti-VEGF therapy for cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-01

AUTHORS

Rakesh K Jain, Dan G Duda, Jeffrey W Clark, Jay S Loeffler

ABSTRACT

Bevacizumab with standard chemotherapy improved overall survival in colorectal and lung cancer patients and progression-free survival in breast cancer patients, but this combination failed to increase survival in patients with previously treated and refractory metastatic breast cancer. Reasons for these contrasting results, the mechanisms behind normalization of tumor vasculature for improved drug and oxygen delivery, and the need for biomarkers and imaging techniques to guide patient selection and protocol design are discussed. More... »

PAGES

24-40

References to SciGraph publications

  • 2004-01-25. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer in NATURE MEDICINE
  • 2002-03. Herceptin acts as an anti-angiogenic cocktail in NATURE
  • 2003-06-01. The biology of VEGF and its receptors in NATURE MEDICINE
  • 2001-09. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy in NATURE MEDICINE
  • 2004-06-01. The anti-angiogenic basis of metronomic chemotherapy in NATURE REVIEWS CANCER
  • 1998-11. A 2-week pretreatment with 13-cis-retinoic acid + interferon-α-2a prior to definitive radiation improves tumor tissue oxygenation in cervical cancers in STRAHLENTHERAPIE UND ONKOLOGIE
  • 2003-06-01. Molecular regulation of vessel maturation in NATURE MEDICINE
  • 2003-03-04. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells in BRITISH JOURNAL OF CANCER
  • 2005-06. News Analysis in NATURE REVIEWS DRUG DISCOVERY
  • 2004-01-06. Angiogenesis inhibitors in clinical development; where are we now and where are we going? in BRITISH JOURNAL OF CANCER
  • 2004-05-01. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer in NATURE REVIEWS DRUG DISCOVERY
  • 1994-07. Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma in ANNALS OF SURGICAL ONCOLOGY
  • 1997-03. Interstitial fluid pressure in intracranial tumours in patients and in rodents in BRITISH JOURNAL OF CANCER
  • 2000-09. Angiogenesis in cancer and other diseases in NATURE
  • 2002-10. Clinical translation of angiogenesis inhibitors in NATURE REVIEWS CANCER
  • 2005-02-14. Inhibition of TGF-β modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma in LABORATORY INVESTIGATION
  • 2002-11-01. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? in NATURE REVIEWS CANCER
  • 2002. The Role of Neuropilin in Vascular and Tumor Biology in NEUROPILIN
  • 2005-06-20. Repopulation of cancer cells during therapy: an important cause of treatment failure in NATURE REVIEWS CANCER
  • 1996-06. A systems approach to cancer therapy in CANCER AND METASTASIS REVIEWS
  • 2003-06-10. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 in BRITISH JOURNAL OF CANCER
  • 2005-12-14. Angiogenesis in life, disease and medicine in NATURE
  • 2005-02-21. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells in ONCOGENE
  • 2005-06-05. Multi-kinase inhibitors create buzz at ASCO in NATURE BIOTECHNOLOGY
  • 2005-05-01. ATM regulates target switching to escalating doses of radiation in the intestines in NATURE MEDICINE
  • Journal

    TITLE

    Nature Reviews Clinical Oncology

    ISSUE

    1

    VOLUME

    3

    Author Affiliations

    Related Patents

  • Her-1, Her-3 And Igf-1r Compositions And Uses Thereof
  • Compositions And Methods For The Delivery Of Oxygen
  • Method For Predicting The Outcome Of A Treatment With Aflibercept Of A Patient Suspected To Suffer From A Cancer
  • Compounds For The Treatment Of Neurodegenerative And Metabolic Disorders
  • Compositions And Methods For The Delivery Of Oxygen
  • Substituted Thiazolopyrimidines
  • Imidazo[1,2-B][1,2,4]Triazines As C-Met Inhibitors
  • Il-8 Level Based Method Of Predicting The Outcome Of Colon Cancer Treatment
  • Compounds For Inhibiting Cell Proliferation In Egfr-Driven Cancers
  • Uracil Derivatives As Axl And C-Met Kinase Inhibitors
  • Neuropilin Antagonists
  • Salts Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Yl-Methyl)-Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide And Processes Related To Preparing The Same
  • Binding Polypeptides With Diversified And Consensus Vh/Vl Hypervariable Sequences
  • Single Nucleotide Polymorphisms In The Promoter Of Vegfa Gene And Their Use As Predictive Markers For Anti-Vegf Treatments
  • Human Pd1 Peptide Vaccines And Uses Thereof
  • Neuropilin Antagonists
  • Binding Polypeptides With Diversified And Consensus Vh/Vl Hypervariable Sequences
  • Hydrogel Polymeric Compositions And Methods
  • Anti-Invasive Compounds
  • Antibodies That Bind To Jagged 1
  • Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
  • Compounds That Modulate Egfr Activity And Methods For Treating Or Preventing Conditions Therewith
  • Compositions And Methods For The Delivery Of Nitric Oxide
  • Methods And Compositions For Targeted Imaging
  • Salts Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Yl-Methyl)-Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide And Processes Related To Preparing The Same
  • Adhesive Hydrogels For Ophthalmic Drug Delivery
  • Composition Comprising Aflibercept, Folinic Acid, 5-Fluorouracil (5-Fu) And Irinotecan (Folfiri)
  • Compositions And Methods For The Delivery Of Nitric Oxide
  • Salts Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Yl-Methyl)-Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide And Processes Related To Preparing The Same
  • Targeted Treatment Of Anerobic Cancer
  • Phosphorus Derivatives As Kinase Inhibitors
  • Her-1, Her-3 And Igf-1r Compositions And Uses Thereof
  • Compositions And Methods For The Delivery Of Oxygen
  • Anti-Neuropilin Antibodies And Methods Of Use
  • Hydrogel Polymeric Compositions And Methods
  • Neuropilin Antagonists
  • Hydrogel Polymeric Compositions And Methods
  • Methods For Inhibiting Cell Proliferation In Alk-Driven Cancers
  • Medical Organogel Processes And Compositions
  • Imidazotriaines And Imidazopyrimidines As Kinase Inhibitors
  • Tumor Therapy With An Anti-Vegf Antibody
  • Drug Delivery Through Hydrogel Plugs
  • Imidazotriaines And Imidazopyrimidines As Kinase Inhibitors
  • Hydrogel Polymeric Compositions And Methods
  • Hydrogel Polymeric Compositions And Methods
  • Drug Delivery From Hydrogels
  • Targeted Treatment Of Anerobic Cancer
  • Neuropilin Antagonists
  • Thienopyrimidines
  • Drug Delivery Through Hydrogel Plugs
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/ncponc0403

    DOI

    http://dx.doi.org/10.1038/ncponc0403

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1035025701

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/16407877


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Angiogenesis Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal, Humanized", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bevacizumab", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biomarkers, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clinical Trials, Phase III as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neovascularization, Pathologic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein-Tyrosine Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Vascular Endothelial Growth Factors", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "MGH, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.32224.35", 
              "name": [
                "Tumor Biology at Harvard Medical School (HMS)", 
                "Edwin L Steele Laboratory for Tumor Biology at Massachusetts General Hospital (MGH)", 
                "HMS", 
                "MGH", 
                "MGH Cancer Center", 
                "Dana-Farber/Partners Cancer Care", 
                "HMS", 
                "MGH, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Jain", 
            "givenName": "Rakesh K", 
            "id": "sg:person.01340416322.96", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340416322.96"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "MGH, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.32224.35", 
              "name": [
                "Tumor Biology at Harvard Medical School (HMS)", 
                "Edwin L Steele Laboratory for Tumor Biology at Massachusetts General Hospital (MGH)", 
                "HMS", 
                "MGH", 
                "MGH Cancer Center", 
                "Dana-Farber/Partners Cancer Care", 
                "HMS", 
                "MGH, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Duda", 
            "givenName": "Dan G", 
            "id": "sg:person.01237474607.21", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237474607.21"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "MGH, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.32224.35", 
              "name": [
                "Tumor Biology at Harvard Medical School (HMS)", 
                "Edwin L Steele Laboratory for Tumor Biology at Massachusetts General Hospital (MGH)", 
                "HMS", 
                "MGH", 
                "MGH Cancer Center", 
                "Dana-Farber/Partners Cancer Care", 
                "HMS", 
                "MGH, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Clark", 
            "givenName": "Jeffrey W", 
            "id": "sg:person.011711024742.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011711024742.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "MGH, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.32224.35", 
              "name": [
                "Tumor Biology at Harvard Medical School (HMS)", 
                "Edwin L Steele Laboratory for Tumor Biology at Massachusetts General Hospital (MGH)", 
                "HMS", 
                "MGH", 
                "MGH Cancer Center", 
                "Dana-Farber/Partners Cancer Care", 
                "HMS", 
                "MGH, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Loeffler", 
            "givenName": "Jay S", 
            "id": "sg:person.0670037777.04", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670037777.04"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/bjc.1997.148", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020183468", 
              "https://doi.org/10.1038/bjc.1997.148"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-1-4615-0119-0_3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004215273", 
              "https://doi.org/10.1007/978-1-4615-0119-0_3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1208246", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042851524", 
              "https://doi.org/10.1038/sj.onc.1208246"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd1768", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006224824", 
              "https://doi.org/10.1038/nrd1768"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6601005", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044464024", 
              "https://doi.org/10.1038/sj.bjc.6601005"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf03187139", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025273729", 
              "https://doi.org/10.1007/bf03187139"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1650", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026450668", 
              "https://doi.org/10.1038/nrc1650"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0603-685", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023460594", 
              "https://doi.org/10.1038/nm0603-685"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1237", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020754853", 
              "https://doi.org/10.1038/nm1237"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/35025220", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043028620", 
              "https://doi.org/10.1038/35025220"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/labinvest.3700252", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014059182", 
              "https://doi.org/10.1038/labinvest.3700252"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc925", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015283659", 
              "https://doi.org/10.1038/nrc925"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6601401", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007664387", 
              "https://doi.org/10.1038/sj.bjc.6601401"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6600811", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008965461", 
              "https://doi.org/10.1038/sj.bjc.6600811"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/416279b", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035406433", 
              "https://doi.org/10.1038/416279b"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature04478", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011948458", 
              "https://doi.org/10.1038/nature04478"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1369", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019159796", 
              "https://doi.org/10.1038/nrc1369"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf03038294", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028287402", 
              "https://doi.org/10.1007/bf03038294"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc905", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017804909", 
              "https://doi.org/10.1038/nrc905"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0603-669", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031340920", 
              "https://doi.org/10.1038/nm0603-669"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0901-987", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053699875", 
              "https://doi.org/10.1038/nm0901-987"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd1381", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006489607", 
              "https://doi.org/10.1038/nrd1381"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm988", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003700365", 
              "https://doi.org/10.1038/nm988"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00437479", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007205974", 
              "https://doi.org/10.1007/bf00437479"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0605-639", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033074581", 
              "https://doi.org/10.1038/nbt0605-639"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2006-01", 
        "datePublishedReg": "2006-01-01", 
        "description": "Bevacizumab with standard chemotherapy improved overall survival in colorectal and lung cancer patients and progression-free survival in breast cancer patients, but this combination failed to increase survival in patients with previously treated and refractory metastatic breast cancer. Reasons for these contrasting results, the mechanisms behind normalization of tumor vasculature for improved drug and oxygen delivery, and the need for biomarkers and imaging techniques to guide patient selection and protocol design are discussed.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/ncponc0403", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2435727", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1034153", 
            "issn": [
              "1759-4774", 
              "1759-4782"
            ], 
            "name": "Nature Reviews Clinical Oncology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "3"
          }
        ], 
        "keywords": [
          "cancer patients", 
          "refractory metastatic breast cancer", 
          "phase III clinical trials", 
          "progression-free survival", 
          "metastatic breast cancer", 
          "anti-VEGF therapy", 
          "breast cancer patients", 
          "lung cancer patients", 
          "standard chemotherapy", 
          "overall survival", 
          "patient selection", 
          "clinical trials", 
          "breast cancer", 
          "oxygen delivery", 
          "tumor vasculature", 
          "patients", 
          "survival", 
          "cancer", 
          "improved drugs", 
          "chemotherapy", 
          "colorectal", 
          "therapy", 
          "trials", 
          "biomarkers", 
          "vasculature", 
          "drugs", 
          "delivery", 
          "normalization", 
          "mechanism", 
          "need", 
          "combination", 
          "reasons", 
          "results", 
          "protocol design", 
          "technique", 
          "selection", 
          "lessons", 
          "design"
        ], 
        "name": "Lessons from phase III clinical trials on anti-VEGF therapy for cancer", 
        "pagination": "24-40", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1035025701"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/ncponc0403"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "16407877"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/ncponc0403", 
          "https://app.dimensions.ai/details/publication/pub.1035025701"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:25", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_421.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/ncponc0403"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/ncponc0403'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/ncponc0403'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/ncponc0403'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/ncponc0403'


     

    This table displays all metadata directly associated to this object as RDF triples.

    276 TRIPLES      21 PREDICATES      101 URIs      68 LITERALS      19 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/ncponc0403 schema:about N24ac8e31848845459fa16b84b56806d4
    2 N32a509dac2e8479b96dd77ede204cd2d
    3 N32b33d2460a943a1960ab1c1cadade26
    4 N330bdc0a549c41d8bb07018033b7cd0a
    5 N67e1671f326f4201bb43ac63149c2ad1
    6 N80ed6e519bf5450f8db47485573c6edb
    7 N90bd7a85b4b04ecaaa185aefef452106
    8 N954fd6b03a8f4cbdb3e31483fdd388d0
    9 N98b34e0093a646a89f4cd665d00fc5f3
    10 Na9910ebc551c43398dac9b8a47589925
    11 Nc2bf7ecd6d28426d9a848329c9c42176
    12 Nfbb578009ab8422e9ee5647cb5e82c48
    13 anzsrc-for:11
    14 anzsrc-for:1112
    15 schema:author Ne429e6b99e124e3a80384fd803ef4b01
    16 schema:citation sg:pub.10.1007/978-1-4615-0119-0_3
    17 sg:pub.10.1007/bf00437479
    18 sg:pub.10.1007/bf03038294
    19 sg:pub.10.1007/bf03187139
    20 sg:pub.10.1038/35025220
    21 sg:pub.10.1038/416279b
    22 sg:pub.10.1038/bjc.1997.148
    23 sg:pub.10.1038/labinvest.3700252
    24 sg:pub.10.1038/nature04478
    25 sg:pub.10.1038/nbt0605-639
    26 sg:pub.10.1038/nm0603-669
    27 sg:pub.10.1038/nm0603-685
    28 sg:pub.10.1038/nm0901-987
    29 sg:pub.10.1038/nm1237
    30 sg:pub.10.1038/nm988
    31 sg:pub.10.1038/nrc1369
    32 sg:pub.10.1038/nrc1650
    33 sg:pub.10.1038/nrc905
    34 sg:pub.10.1038/nrc925
    35 sg:pub.10.1038/nrd1381
    36 sg:pub.10.1038/nrd1768
    37 sg:pub.10.1038/sj.bjc.6600811
    38 sg:pub.10.1038/sj.bjc.6601005
    39 sg:pub.10.1038/sj.bjc.6601401
    40 sg:pub.10.1038/sj.onc.1208246
    41 schema:datePublished 2006-01
    42 schema:datePublishedReg 2006-01-01
    43 schema:description Bevacizumab with standard chemotherapy improved overall survival in colorectal and lung cancer patients and progression-free survival in breast cancer patients, but this combination failed to increase survival in patients with previously treated and refractory metastatic breast cancer. Reasons for these contrasting results, the mechanisms behind normalization of tumor vasculature for improved drug and oxygen delivery, and the need for biomarkers and imaging techniques to guide patient selection and protocol design are discussed.
    44 schema:genre article
    45 schema:isAccessibleForFree false
    46 schema:isPartOf N878b774a143140af8fa5f031c935b54d
    47 Nbd4cda482585484691e699d226126829
    48 sg:journal.1034153
    49 schema:keywords anti-VEGF therapy
    50 biomarkers
    51 breast cancer
    52 breast cancer patients
    53 cancer
    54 cancer patients
    55 chemotherapy
    56 clinical trials
    57 colorectal
    58 combination
    59 delivery
    60 design
    61 drugs
    62 improved drugs
    63 lessons
    64 lung cancer patients
    65 mechanism
    66 metastatic breast cancer
    67 need
    68 normalization
    69 overall survival
    70 oxygen delivery
    71 patient selection
    72 patients
    73 phase III clinical trials
    74 progression-free survival
    75 protocol design
    76 reasons
    77 refractory metastatic breast cancer
    78 results
    79 selection
    80 standard chemotherapy
    81 survival
    82 technique
    83 therapy
    84 trials
    85 tumor vasculature
    86 vasculature
    87 schema:name Lessons from phase III clinical trials on anti-VEGF therapy for cancer
    88 schema:pagination 24-40
    89 schema:productId N230a85ebb47d4ed48f52ba2a50867bc0
    90 N46c1dcc3851e4bb2bde06b675149f7d2
    91 N71f2fbef1d914105b85e6bd21c118f86
    92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035025701
    93 https://doi.org/10.1038/ncponc0403
    94 schema:sdDatePublished 2022-12-01T06:25
    95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    96 schema:sdPublisher N761c5b70931240b49a24984671a07186
    97 schema:url https://doi.org/10.1038/ncponc0403
    98 sgo:license sg:explorer/license/
    99 sgo:sdDataset articles
    100 rdf:type schema:ScholarlyArticle
    101 N230a85ebb47d4ed48f52ba2a50867bc0 schema:name pubmed_id
    102 schema:value 16407877
    103 rdf:type schema:PropertyValue
    104 N24ac8e31848845459fa16b84b56806d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    105 schema:name Antineoplastic Agents
    106 rdf:type schema:DefinedTerm
    107 N32a509dac2e8479b96dd77ede204cd2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    108 schema:name Neoplasms
    109 rdf:type schema:DefinedTerm
    110 N32b33d2460a943a1960ab1c1cadade26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Biomarkers, Tumor
    112 rdf:type schema:DefinedTerm
    113 N330bdc0a549c41d8bb07018033b7cd0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name Neovascularization, Pathologic
    115 rdf:type schema:DefinedTerm
    116 N46c1dcc3851e4bb2bde06b675149f7d2 schema:name doi
    117 schema:value 10.1038/ncponc0403
    118 rdf:type schema:PropertyValue
    119 N67e1671f326f4201bb43ac63149c2ad1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Clinical Trials, Phase III as Topic
    121 rdf:type schema:DefinedTerm
    122 N71f2fbef1d914105b85e6bd21c118f86 schema:name dimensions_id
    123 schema:value pub.1035025701
    124 rdf:type schema:PropertyValue
    125 N761c5b70931240b49a24984671a07186 schema:name Springer Nature - SN SciGraph project
    126 rdf:type schema:Organization
    127 N80ed6e519bf5450f8db47485573c6edb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Vascular Endothelial Growth Factors
    129 rdf:type schema:DefinedTerm
    130 N878b774a143140af8fa5f031c935b54d schema:volumeNumber 3
    131 rdf:type schema:PublicationVolume
    132 N90bd7a85b4b04ecaaa185aefef452106 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    133 schema:name Antibodies, Monoclonal, Humanized
    134 rdf:type schema:DefinedTerm
    135 N954fd6b03a8f4cbdb3e31483fdd388d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Antibodies, Monoclonal
    137 rdf:type schema:DefinedTerm
    138 N98b34e0093a646a89f4cd665d00fc5f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Protein-Tyrosine Kinases
    140 rdf:type schema:DefinedTerm
    141 Na9910ebc551c43398dac9b8a47589925 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Humans
    143 rdf:type schema:DefinedTerm
    144 Naadde87ebb334e80926624810fc053e8 rdf:first sg:person.01237474607.21
    145 rdf:rest Nbe1ffcb195614877aab3547984712dd3
    146 Nbd4cda482585484691e699d226126829 schema:issueNumber 1
    147 rdf:type schema:PublicationIssue
    148 Nbe1ffcb195614877aab3547984712dd3 rdf:first sg:person.011711024742.39
    149 rdf:rest Nf733f84d8ff047eea5083ba8dc81e8ac
    150 Nc2bf7ecd6d28426d9a848329c9c42176 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Bevacizumab
    152 rdf:type schema:DefinedTerm
    153 Ne429e6b99e124e3a80384fd803ef4b01 rdf:first sg:person.01340416322.96
    154 rdf:rest Naadde87ebb334e80926624810fc053e8
    155 Nf733f84d8ff047eea5083ba8dc81e8ac rdf:first sg:person.0670037777.04
    156 rdf:rest rdf:nil
    157 Nfbb578009ab8422e9ee5647cb5e82c48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Angiogenesis Inhibitors
    159 rdf:type schema:DefinedTerm
    160 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    161 schema:name Medical and Health Sciences
    162 rdf:type schema:DefinedTerm
    163 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    164 schema:name Oncology and Carcinogenesis
    165 rdf:type schema:DefinedTerm
    166 sg:grant.2435727 http://pending.schema.org/fundedItem sg:pub.10.1038/ncponc0403
    167 rdf:type schema:MonetaryGrant
    168 sg:journal.1034153 schema:issn 1759-4774
    169 1759-4782
    170 schema:name Nature Reviews Clinical Oncology
    171 schema:publisher Springer Nature
    172 rdf:type schema:Periodical
    173 sg:person.011711024742.39 schema:affiliation grid-institutes:grid.32224.35
    174 schema:familyName Clark
    175 schema:givenName Jeffrey W
    176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011711024742.39
    177 rdf:type schema:Person
    178 sg:person.01237474607.21 schema:affiliation grid-institutes:grid.32224.35
    179 schema:familyName Duda
    180 schema:givenName Dan G
    181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237474607.21
    182 rdf:type schema:Person
    183 sg:person.01340416322.96 schema:affiliation grid-institutes:grid.32224.35
    184 schema:familyName Jain
    185 schema:givenName Rakesh K
    186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340416322.96
    187 rdf:type schema:Person
    188 sg:person.0670037777.04 schema:affiliation grid-institutes:grid.32224.35
    189 schema:familyName Loeffler
    190 schema:givenName Jay S
    191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670037777.04
    192 rdf:type schema:Person
    193 sg:pub.10.1007/978-1-4615-0119-0_3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004215273
    194 https://doi.org/10.1007/978-1-4615-0119-0_3
    195 rdf:type schema:CreativeWork
    196 sg:pub.10.1007/bf00437479 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007205974
    197 https://doi.org/10.1007/bf00437479
    198 rdf:type schema:CreativeWork
    199 sg:pub.10.1007/bf03038294 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028287402
    200 https://doi.org/10.1007/bf03038294
    201 rdf:type schema:CreativeWork
    202 sg:pub.10.1007/bf03187139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025273729
    203 https://doi.org/10.1007/bf03187139
    204 rdf:type schema:CreativeWork
    205 sg:pub.10.1038/35025220 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043028620
    206 https://doi.org/10.1038/35025220
    207 rdf:type schema:CreativeWork
    208 sg:pub.10.1038/416279b schema:sameAs https://app.dimensions.ai/details/publication/pub.1035406433
    209 https://doi.org/10.1038/416279b
    210 rdf:type schema:CreativeWork
    211 sg:pub.10.1038/bjc.1997.148 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020183468
    212 https://doi.org/10.1038/bjc.1997.148
    213 rdf:type schema:CreativeWork
    214 sg:pub.10.1038/labinvest.3700252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014059182
    215 https://doi.org/10.1038/labinvest.3700252
    216 rdf:type schema:CreativeWork
    217 sg:pub.10.1038/nature04478 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011948458
    218 https://doi.org/10.1038/nature04478
    219 rdf:type schema:CreativeWork
    220 sg:pub.10.1038/nbt0605-639 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033074581
    221 https://doi.org/10.1038/nbt0605-639
    222 rdf:type schema:CreativeWork
    223 sg:pub.10.1038/nm0603-669 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031340920
    224 https://doi.org/10.1038/nm0603-669
    225 rdf:type schema:CreativeWork
    226 sg:pub.10.1038/nm0603-685 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023460594
    227 https://doi.org/10.1038/nm0603-685
    228 rdf:type schema:CreativeWork
    229 sg:pub.10.1038/nm0901-987 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053699875
    230 https://doi.org/10.1038/nm0901-987
    231 rdf:type schema:CreativeWork
    232 sg:pub.10.1038/nm1237 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020754853
    233 https://doi.org/10.1038/nm1237
    234 rdf:type schema:CreativeWork
    235 sg:pub.10.1038/nm988 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003700365
    236 https://doi.org/10.1038/nm988
    237 rdf:type schema:CreativeWork
    238 sg:pub.10.1038/nrc1369 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019159796
    239 https://doi.org/10.1038/nrc1369
    240 rdf:type schema:CreativeWork
    241 sg:pub.10.1038/nrc1650 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026450668
    242 https://doi.org/10.1038/nrc1650
    243 rdf:type schema:CreativeWork
    244 sg:pub.10.1038/nrc905 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017804909
    245 https://doi.org/10.1038/nrc905
    246 rdf:type schema:CreativeWork
    247 sg:pub.10.1038/nrc925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015283659
    248 https://doi.org/10.1038/nrc925
    249 rdf:type schema:CreativeWork
    250 sg:pub.10.1038/nrd1381 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006489607
    251 https://doi.org/10.1038/nrd1381
    252 rdf:type schema:CreativeWork
    253 sg:pub.10.1038/nrd1768 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006224824
    254 https://doi.org/10.1038/nrd1768
    255 rdf:type schema:CreativeWork
    256 sg:pub.10.1038/sj.bjc.6600811 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008965461
    257 https://doi.org/10.1038/sj.bjc.6600811
    258 rdf:type schema:CreativeWork
    259 sg:pub.10.1038/sj.bjc.6601005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044464024
    260 https://doi.org/10.1038/sj.bjc.6601005
    261 rdf:type schema:CreativeWork
    262 sg:pub.10.1038/sj.bjc.6601401 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007664387
    263 https://doi.org/10.1038/sj.bjc.6601401
    264 rdf:type schema:CreativeWork
    265 sg:pub.10.1038/sj.onc.1208246 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042851524
    266 https://doi.org/10.1038/sj.onc.1208246
    267 rdf:type schema:CreativeWork
    268 grid-institutes:grid.32224.35 schema:alternateName MGH, Boston, MA, USA
    269 schema:name Dana-Farber/Partners Cancer Care
    270 Edwin L Steele Laboratory for Tumor Biology at Massachusetts General Hospital (MGH)
    271 HMS
    272 MGH
    273 MGH Cancer Center
    274 MGH, Boston, MA, USA
    275 Tumor Biology at Harvard Medical School (HMS)
    276 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...